$546 Million

Agios Pharmaceuticals

Follow-on Offering

Bookrunner, January 2018

Agios Pharmaceuticals
Agios Pharmaceuticals is a biopharmaceutical company in the field of cellular metabolism and adjacent areas of biology, with the goal of making transformative medicines for the treatment of cancer and rare genetic diseases, or RGDs. Agios is developing ivosidenib (brand name TIBSOVO) for the treatment of IDH1 mutant-positive cancers. Ivosidenib is an orally available, selective, potent inhibitor of the mutated IDH1 protein, making it a highly targeted therapy for the treatment of patients with cancers that harbor IDH1 mutations, including those with AML, or cholangiocarcinoma. Additionally, the Company’s lead product candidate in their RGD portfolio, mitapivat, is being developed for the treatment of PK deficiency as well as thalassemia.